ArticleFrontiers in endocrinology2022
Mendelian randomization study supports the causal association between serum cystatin C and risk of diabetic nephropathy.
Article in Frontiers in endocrinology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 24 citations in OpenAlex.
- Gut microbiota implication in diabetic kidney disease: mechanisms and novel therapeutic strategies.Renal failure · 2025Review
- Cystatin C-based equations: Enhancing accuracy in kidney function tests for type 2 diabetes.World journal of nephrology · 2025Article
- [High serum cystatin C is an independent risk factor for poor renal prognosis in IgA nephropathy].Nan fang yi ke da xue xue bao = Journal of Southern Medical University · 2025Article
- Association between obstructive sleep apnea and chronic kidney disease: A cross-sectional and Mendelian randomization study.Medicine · 2025Article
- Multi-feature integrated machine learning prediction model for early nephropathy in elderly living with type 2 diabetes mellitus.Frontiers in endocrinology · 2025Article
- Mendelian Randomization Studies: Opening a New Window in the Study of Metabolic Diseases and Chronic Kidney Disease.Endocrine, metabolic & immune disorders drug targets · 2025Review
- Exploring the Incidence and Risk Factors of Diabetic Nephropathy in Type 1 Diabetes: Insights from a Retrospective Cohort Study in Northwest China.Diabetes, metabolic syndrome and obesity : targets and therapy · 2025Article
- Association of Intraindividual Difference in Cystatin C and Creatinine Estimated Glomerular Filtration Rate With Diabetes.Journal of diabetes research · 2025Article
- Causal association between cystatin C and diabetic retinopathy: A two-sample Mendelian randomization study.Journal of diabetes investigation · 2024Article
- Integrative Analysis by Mendelian Randomization and Large-Scale Single-Cell Transcriptomics Reveals Causal Links between B Cell Subtypes and Diabetic Kidney Disease.Kidney diseases (Basel, Switzerland) · 2024Article
- Association of serum cystatin C level and major adverse cardiovascular events in patients with percutaneous coronary intervention.Cardiovascular diagnosis and therapy · 2024Article
- Hyperuricemia and its related diseases: mechanisms and advances in therapy.Signal transduction and targeted therapy · 2024Review
- The causal effect of inflammatory proteins and immune cell populations on diabetic nephropathy: evidence from Mendelian randomization.International urology and nephrology · 2024Article
- A Cross-Sectional Study of Glomerular Hyperfiltration in Polycystic Ovary Syndrome.International journal of molecular sciences · 2024Article
- Mendelian randomization analysis reveals causal factors behind diabetic nephropathy: evidence, opportunities, and challenges.Frontiers in endocrinology · 2024Review
- Association of Circulating Carbohydrate Antigen 19-9 Level with Type 2 Diabetic Kidney Disease in Chinese Adults: A Cross-Sectional Study.Diabetes, metabolic syndrome and obesity : targets and therapy · 2024Article
- Characterization of peripheral blood inflammatory indicators and OCT imaging biological markers in diabetic retinopathy with or without nephropathy.Frontiers in endocrinology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aims: Cystatin C, an inhibitor of cysteine protease, has been used as a biomarker for estimating glomerular filtration rate. However, the causal relation between cystatin C and diabetic nephropathy remains uncertain. Methods: We assessed the causal effect of cystatin C together with other five serum biomarkers including KIM-1, GDF-15, TBIL, uric acid, and Scr on diabetic nephropathy by Mendelian randomization (MR) analysis. 234 genetic variants were selected as instrumental variables to evaluate the causal effect of cystatin C (N Results: Among the six serum biomarkers, only cystatin C causally associated with diabetic nephropathy (IVW OR: 1.36, 95%CI [1.15, 1.61]). After adjusting for the potential confounders BMI and SBP, cystatin C maintained its causal effect on the DN (OR: 1.17, 95%CI [1.02, 1.33]), which means that the risk of DN increased by 17% with an approximate 1 standard deviation (SD) increment of serum cystatin C level. Two-step MR results indicated that BMI might mediate the causal effect of cystatin C on diabetic nephropathy. Interpretation: Our findings discovered that cystatin C was a risk factor for diabetic nephropathy independent of BMI and SBP in diabetes mellitus patients. Future research is required to illustrate the underlying mechanism and prove targeting circulating cystatin C could be a potential therapy method.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.